Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP2998 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on ASP2998, a putative TROP2 inhibitor (Feb 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP2998 | ASP-2998|ASP 2998 | Limited information is currently available on ASP2998, a putative TROP2 inhibitor (Feb 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07287995 | Phase Ib/II | ASP2998 ASP2998 + Pembrolizumab ASP2998 + Enfortumab vedotin-ejfv ASP2998 + Carboplatin + Pembrolizumab ASP2998 + Enfortumab vedotin-ejfv + Pembrolizumab | A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors | Recruiting | USA | 0 |